phrykt

X4 Pharmaceuticals, Inc (XFOR): who owns it and who trades it

As of Nov 16, 2026, XFOR insiders reported 5 open-market sales worth $463K and 1 purchase worth $11.9K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Adam R Craig (Chair), with $211K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling X4 Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns XFOR

88 funds and institutions reported XFOR shares worth $478M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Morgan Stanley with 10.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Morgan Stanley10.4%
FMR LLC (Fidelity)9.2%
Bain Capital Life Sciences Investors, LLC8.8%
Perceptive Advisors LLC8.7%
Kalehua Capital Management LLC8.2%
Saturn V Capital Management LP7.7%
Empery Asset Management, LP7.6%
Deep Track Capital, LP6.5%
BlackRock, Inc.6.1%
Nantahala Capital Management, LLC5.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Morgan Stanley9.46M10.41%$44.2M-0%
FMR LLC (Fidelity)8.32M9.15%$38.9M+3%
Bain Capital Life Sciences Investors, LLC7.97M8.76%$37.2MNo change
Perceptive Advisors LLC7.93M8.73%$37M+18%
Kalehua Capital Management LLC7.45M8.19%$34.8MNo change
Saturn V Capital Management LP6.97M7.67%$32.6M+8%
Empery Asset Management, LP6.93M7.62%$32.4M-23%
Deep Track Capital, LP5.88M6.47%$27.5M-7%
BlackRock, Inc.5.55M6.11%$25.9M+358%
Nantahala Capital Management, LLC4.90M5.39%$22.9M+100%
Vanguard Capital Management LLC3.72M4.09%$17.4M+6%
Rosalind Advisors, Inc.3.21M3.54%$15MNo change
Braidwell LP2.92M3.21%$13.6M-11%
Blackstone Inc.2.68M2.95%$12.5MNo change
Trails Edge Capital Partners, LP2.57M2.83%$12MNo change
Bvf Inc2.23M2.46%$10.4MNo change
Geode Capital Management, LLC2.10M2.31%$9.8M+123%
Venrock Adviser, LLC1.93M2.13%$9M+485%
Samsara Biocapital, LLC1.40M1.53%$6.5M-24%
State Street Corp1.30M1.43%$6.1M+221%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, XFOR insiders reported $11.9K of open-market purchases and $463K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$11.9K
1 trades, 1 people
Sales, 12 months
$463K
5 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 16, 2026
Filed Oct 19, 2026

Purchases and sales by month

$320K$320KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 16, 2026Adam R CraigChairPurchase4,600$2.58$11.9KForm 4
Oct 1, 2026David KirskeCFOSale11,767$2.86$33.7KForm 4
Aug 12, 2026John VolponePresidentSale24,576$4.44$109KForm 4
Aug 12, 2026Adam R CraigChairSale47,436$4.44$211KForm 4
Jun 30, 2026David KirskeCFOSale8,543$4.26$36.4KForm 4
May 12, 2026David KirskeCFOSale16,961$4.29$72.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Adam R CraigExecutive Chairman, Director$11.9K$211KOct 16, 2026
David KirskeChief Financial Officer–$143KOct 1, 2026
John VolponePresident–$109KAug 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

XFOR short interest

Moderate short interest. 8.0% of XFOR shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went up 173%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.97M XFOR shares were sold short, 8.0% of the shares outstanding, up 6.4% from the report before. At the average daily volume of 734,226 shares, buying them all back would take about 10.9 trading days (days to cover).

Shares short, % of all shares

8.04%May 15Oct 309.07%

Days to cover

10.9May 15Oct 3014.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.97M8.04%+6%734,22610.9
Oct 15, 20267.49M7.56%-1%599,10612.5
Sep 30, 20267.59M7.66%-8%1.26M6.0
Sep 15, 20268.24M8.31%+15%1.16M7.1
Aug 31, 20267.19M7.25%+0%560,02712.8
Aug 14, 20267.16M7.23%-2%803,5678.9
Jul 31, 20267.30M7.36%+12%572,77612.8
Jul 15, 20266.50M7.15%+18%663,9019.8
Jun 30, 20265.51M6.06%+32%1.59M3.5
Jun 15, 20264.18M4.60%+24%421,3939.9
May 29, 20263.37M3.71%+15%363,1159.3
May 15, 20262.92M3.22%-6%344,2268.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

X4 Pharmaceuticals company events

X4 Pharmaceuticals filed 7 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026AnnouncementX4 Pharmaceuticals, Inc. will be posting to its website an investor presentation to be used in the Company’s October 29, 2029 Investor Day event. Filing
  2. Oct 8, 2026AgreementX4 Pharmaceuticals, Inc. and its wholly owned subsidiary, X4 Therapeutics, Inc. (together with the Company, the “Borrowers”), entered into a Loan and Security Agreement with K2 HealthVentures LLC, as administrative agent (in such capacity, the “Administrative Agent”) and as a lender, the other… Filing
  3. Sep 9, 2026AnnouncementX4 Pharmaceuticals, Inc. posted an updated corporate presentation on the Company’s website. Filing
  4. Sep 8, 2026AnnouncementX4 Pharmaceuticals, Inc. issued a press release announcing the positive outcome of the Company’s Type C Meeting with the U.S. Food and Drug Administration related to the global 4WARD Phase 3 clinical trial. Filing
  5. Jul 1, 2026LeadershipOf X4 Pharmaceuticals, Inc. appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026. Filing
  6. May 13, 2026LeadershipAmended an earlier report. At the Annual Meeting, the Company’s stockholders approved the Company’s Second Amended and Restated 2017 Equity Incentive Plan (as so amended, the “Plan”) to increase the number of shares available for issuance under the Plan by 1,500,000 shares. Filing
  7. May 12, 2026LeadershipAt the Annual Meeting, the Company’s stockholders approved the Company’s Second Amended and Restated 2017 Equity Incentive Plan (as so amended, the “Plan”) to increase the number of shares available for issuance under the Plan by 1,500,000 shares. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

X4 Pharmaceuticals financials

Famous investors that hold XFOR

3 of the 50 well-known investors we track reported holding XFOR in their latest 13F filing. The largest position is Ken Griffin's, worth $436K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026150,205$436K0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026115,524$335K0.0%+538%
Steve Cohen · Point72 Asset ManagementQ3 202693,565$271K0.0%+128%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named XFOR in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Deep Track Capital, LP13G/A6.6%
Nov 16, 2026Venrock Healthcare Capital Partners III, L.P.13G/A7.6%
Nov 16, 2026Deep Track Capital, LP13G/A6.6%
Nov 16, 2026Venrock Healthcare Capital Partners III, L.P.13G/A7.6%
Nov 13, 2026Coastlands Capital LP13G/A10.0%
Nov 13, 2026Coastlands Capital LP13G/A10.0%
Oct 7, 2026FMR LLC13G/A4.6%
Oct 7, 2026FMR LLC13G/A4.6%

Questions about X4 Pharmaceuticals, Inc (XFOR) stock

Who owns the most XFOR stock?

The largest reported owner of X4 Pharmaceuticals, Inc (XFOR) is Morgan Stanley, with 10.4% of the company. In total, 88 funds and institutions reported holding XFOR at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are XFOR insiders buying or selling?

In the last 12 months, XFOR insiders reported 1 open-market purchase worth $11.9K and 5 sales worth $463K. The latest trade was on Oct 16, 2026. See every trade.

What is the short interest in XFOR?

As of Oct 30, 2026, 7.97M XFOR shares were sold short, 8.0% of the shares outstanding, up 6.4% from the report before. At the average daily volume of 734,226 shares, buying them all back would take about 10.9 trading days (days to cover). See the history.

Which famous investors hold XFOR?

3 of the 50 well-known investors we track reported XFOR in their latest 13F filing, including Ken Griffin, Jim Simons, Steve Cohen. The largest position is worth $436K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.